Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds RSS Feed PharmiWeb Candidate Blog RSS Feed PharmiWeb Client Blog


Press Release

Global DNA Gyrase Subunit B (EC Pipeline Review 2016 Featuring Abgentis, AstraZeneca, Daiichi Sankyo Company & Merck & Co. - Research and Markets

Research and Markets
Posted on: 31 Aug 16

Research and Markets has announced the addition of the "DNA Gyrase Subunit B (EC - Pipeline Review, H1 2016" report to their offering.

DNA Gyrase Subunit B (EC pipeline target constitutes close to 7 molecules, out of which approximately 7 molecules are developed by companies.

Furthermore, DNA Gyrase Subunit B (EC DNA gyrase is an essential bacterial enzyme that catalyzes the ATP-dependent negative super-coiling of double-stranded closed-circular DNA. DNA gyrase has two subunits. One of the subunit is B which introduces negative supercoils. Subunit B is selectively inactivated by antibiotics such as coumermycin A1 and novobiocin. Inhibition of either subunit blocks supertwisting activity.

The report 'DNA Gyrase Subunit B - Pipeline Review, H1 2016' outlays comprehensive information on the DNA Gyrase Subunit B (EC targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in DNA Gyrase Subunit B (EC targeted therapeutics development, features dormant and discontinued projects and latest news and press releases. Currently, The molecules developed by Companies in Phase I, Preclinical, Discovery and Unknown stages are 1, 3, 2 and 1 respectively.

Key Topics Covered:

  1. Introduction
  2. DNA Gyrase Subunit B Overview
  3. Therapeutics Development
  4. Pipeline Products for DNA Gyrase Subunit B - Overview
  5. Pipeline Products for DNA Gyrase Subunit B - Comparative Analysis
  6. DNA Gyrase Subunit B - Therapeutics under Development by Companies
  7. DNA Gyrase Subunit B - Therapeutics under Investigation by Universities/Institutes
  8. DNA Gyrase Subunit B Products Glance
  9. Late Stage Products
  10. Clinical Stage Products
  11. Early Stage Products
  12. DNA Gyrase Subunit B - Products under Development by Companies
  13. DNA Gyrase Subunit B - Products under Investigation by Universities/Institutes
  14. DNA Gyrase Subunit B - Companies Involved in Therapeutics Development
  • Abgentis Limited
  • AstraZeneca Plc
  • Daiichi Sankyo Company, Limited
  • Merck & Co., Inc.

For more information about this report visit

Related Topics: Enzymes

View source version on

Business Wire

Last updated on: 31/08/2016

Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.